http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10100366-B2
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_b5dd388a5130b0bdede0fdfc6c2af6ed http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_b5d8ac82a79f42f9c79245d3ea8b140b |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-106 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-156 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-47 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6886 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-6886 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-47 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-68 |
| filingDate | 2016-11-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2018-10-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fcefa34ebc9b943959702a92839e0e09 |
| publicationDate | 2018-10-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | US-10100366-B2 |
| titleOfInvention | Methods of detecting cancers sensitive to cabozantinib |
| abstract | The emergence of resistance to targeted therapy is a recurrent clinical challenge and requires development and validation of secondary agents with improved activity. Accompanied by experimental cell-based and structural validation, this report of a near complete response to cabozantinib in a ROS1-rearranged lung adenocarcinoma patient with acquired resistance to crizotinib mediated by a novel CD74-ROS1 D2033N solvent-front mutation provides the first clinical example of crizotinib resistance overcome by targeted therapy in a ROS1-rearranged malignancy. |
| priorityDate | 2015-11-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 332.